115 related articles for article (PubMed ID: 15054690)
21. Carvedilol.
Frishman WH
Indian Heart J; 1999; 51(3):325-32. PubMed ID: 10624077
[No Abstract] [Full Text] [Related]
22. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
[TBL] [Abstract][Full Text] [Related]
23. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
[TBL] [Abstract][Full Text] [Related]
24. Nebivolol: a new beta blocker on the horizon.
Katira R; Chauhan A
Indian Heart J; 2000; 52(1):86-8. PubMed ID: 10820942
[No Abstract] [Full Text] [Related]
25. [Beta blockers in heart failure. Experiences and recommendations for clinical use. ANMCO-Area Heart Failure].
Sinagra G; Boccanelli A; Camerini F; Gavazzi A; Gronda E; Maggioni AP; Opasich C; Rapezzi C; Scherillo M; Tavazzi L
G Ital Cardiol; 1998 Jan; 28(1):61-70. PubMed ID: 9493048
[No Abstract] [Full Text] [Related]
26. [Comparative study in heart failure. Which beta blocker saves more life time?].
MMW Fortschr Med; 2003 Oct; 145(40):52. PubMed ID: 14603606
[No Abstract] [Full Text] [Related]
27. The impact of beta-blockade on mortality rates in patients with congestive heart failure.
Goldstein S; Gottlieb SS
J Card Fail; 2000 Jun; 6(2 Suppl 1):15-24. PubMed ID: 10908094
[TBL] [Abstract][Full Text] [Related]
28. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
29. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
DiNicolantonio JJ; Hackam DG
Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):13-25. PubMed ID: 22149523
[TBL] [Abstract][Full Text] [Related]
30. Oxidation phenotype and beta-blockers.
N Engl J Med; 1983 Apr; 308(16):964-6. PubMed ID: 6132337
[No Abstract] [Full Text] [Related]
31. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
[TBL] [Abstract][Full Text] [Related]
32. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
33. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
34. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Swedberg K
Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
[No Abstract] [Full Text] [Related]
35. Carvedilol for heart failure.
Med Lett Drugs Ther; 1997 Sep; 39(1010):89-91. PubMed ID: 9323960
[No Abstract] [Full Text] [Related]
36. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
McBride BF; White CM
J Clin Pharmacol; 2005 Jan; 45(1):6-24. PubMed ID: 15601801
[TBL] [Abstract][Full Text] [Related]
37. [Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Kawano S
Nihon Rinsho; 2007 May; 65 Suppl 5():91-7. PubMed ID: 17571371
[No Abstract] [Full Text] [Related]
38. [The clinical pharmacology of beta-adrenoblockers].
Sychev DA; Ramenskaia GV; Ignat'ev IV; Smirnikhina SA; Kazakov RE; Kukes VG
Klin Med (Mosk); 2006; 84(3):4-9. PubMed ID: 16758913
[TBL] [Abstract][Full Text] [Related]
39. Comparative review of beta-blocking agents.
Jackson EA; Sullman SA
Conn Med; 1984 Apr; 48(4):213-5. PubMed ID: 6143648
[No Abstract] [Full Text] [Related]
40. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent.
Thürmann PA; Haack S; Werner U; Szymanski J; Haase G; Drewelow B; Reimann IR; Hippius M; Siegmund W; May K; Hasford J
Clin Pharmacol Ther; 2006 Nov; 80(5):551-3. PubMed ID: 17112812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
